Inato’s Chief Strategy Officer Liz Beatty recently sat down with Liam Eves, host of The Endpoint Podcast, to discuss trends in clinical research with new technologies, decentralized trials, and an increasing emphasis on inclusive, accessible research. Their conversation concerned the changes emerging in the clinical trial realm and how a post-COVID world is shifting the way we look at clinical research. Liz broke down Inato’s role in that shift and our goal to reinvent how sites and sponsors connect.
“We completely changed the model to say: let the sites self-identify, let it not be driven by the sponsors,” said Liz, explaining exactly how Inato is flipping the standard model of site selection. Inato’s approach is centered around allowing the sites to choose the trials that are best for their capabilities and patients. The standard model prohibits sites from proactively doing this and instead, the same, few, large sites are repeatedly chosen for research. By flipping the model, we can make research more accessible, inclusive and efficient.
“Every day we’re getting sites who would have never had an opportunity to participate in research for these trials,” Liz said. “We’re getting them a seat at the table.”
Now, with access to trial opportunities, small, local sites are able to bring valuable patient populations to clinical research. These community sites have already cracked the code to promote diversity and inclusivity in their research: the investigators are personally committed to serving underrepresented patient populations. They have built long term, trusting relationships in their community, leading to a quality of care that puts the patient first.
To hear more about how Inato is breaking the mold in clinical trials and why we’re driven to increase access for community sites, listen to Liz and Liam’s conversation on The Endpoint Podcast.